Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

s. Injection site reaction, generally considered mild, was the most commonly reported adverse event with ARCALYST®.  

Two other studies are ongoing in the Phase 3 program.  The global PRE-SURGE 2 study, which has a similar trial design as PRE-SURGE 1, is evaluating the number of gout flares per patient over the first 16 weeks of initiation of allopurinol therapy.  The global RE-SURGE study is evaluating the safety of ARCALYST® versus placebo over 16 weeks in patients who are at risk for gout flares because they are taking uric acid-lowering drug treatment.  PRE-SURGE 2 and RE-SURGE are fully enrolled, and the Company expects to have initial data from both studies in the first quarter of 2011.  Regeneron owns worldwide rights to ARCALYST®.  

Aflibercept (VEGF Trap) – OncologyAflibercept, also known as VEGF Trap, is a fusion protein that is designed to bind VEGF-A and PLGF, proteins that are involved in the abnormal growth of new blood vessels in solid tumors.

Aflibercept is being developed worldwide by Regeneron and its collaborator, the sanofi-aventis Group, for the potential treatment of solid tumors.  Three randomized, double-blind, Phase 3 trials, all of which are fully enrolled, are evaluating combinations of standard chemotherapy regimens with either aflibercept or placebo for the treatment of cancer.  One trial (VELOUR) is evaluating aflibercept as a 2nd-line treatment for metastatic colorectal cancer in combination with FOLFIRI (folinic acid [leucovorin], 5-fluorouracil, and irinotecan).  A second trial (VITAL) is evaluating aflibercept as a 2nd-line treatment for locally advanced or metastatic non-small cell lung cancer in combination with docetaxel.  The third trial (VENICE) is evaluating aflibercept as a 1st-line treatment for metastatic, castration-resistant prostate cancer in combination with docetaxel/prednisone.  

Final results from the VITAL and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ... that the Company will release results for the second ... the opening of the U.S. financial markets. The Company ... 8:30 a.m. ET to discuss results and highlights of ... be used during the call will be available on ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
(Date:7/31/2014)... 31, 2014 Hovione today announced that ... has successfully passed a pre-approval inspection by the US Food ... by the FDA Consumer Safety Officer, Ms. Britanny Terhar ... st July and concluded on the 25 th . ... principles and guidelines of Good Manufacturing Practices (GMP) and no ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
... Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... vice president and chief commercial officer. Mr. Palekar will be ... "Rohan has an outstanding track record of success in ... CEO of Avanir. "I am delighted that we were able ...
... On March 8, attorneys at the Arizona law firm ... for failure to pay its employees the overtime wages to ... (FLSA). The Complaint was filed in the United States District Court ... pharmaceutical reps employed in the U.S. from March 2009 until ...
Cached Medicine Technology:Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals 2
(Date:7/31/2014)... Hudson County, NJ (PRWEB) July 31, 2014 ... that a leading gastroenterologist, Dr. Masood Rizvi, has ... system welcomes Dr. Rizvi to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/31/2014)... You’re having a wonderful summer—sunning, gardening, enjoying BBQs ... chills and fever, headache, stiff neck, achey joints, and a ... it could actually be the first sign of Lyme ... is greater than you might think. Until last year, it ... U.S. annually. But the Centers for Disease Control and Prevention ...
(Date:7/31/2014)... 31, 2014 Two years in the ... in-depth overview of the research behind the latest scientific ... Davis and Vesanto Melina, well-respected authorities on plant-based nutrition, ... are safe and adequate for people at all stages ... as athletes and pregnant or lactating women. , ...
(Date:7/31/2014)... 31, 2014 Most mommy blogs are ... main purpose is to attract all mothers from all ... a particular group; whether its high fashion or child ... that everything on the Internet was so segmented. “I ... a particular topic and then search Google to get ...
(Date:7/31/2014)... Many black women put concerns about their hair above ... by the U.S. Centers for Disease Control and Prevention ... United States are overweight or obese. Yet some of ... have their hair restyled or restraightened, the University of ... researchers also noted a shift toward more "low-maintenance" hairstyles, ...
Breaking Medicine News(10 mins):Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:New Book Presents Health Professionals With A Fully-Referenced, Meticulous Overview of the Research on Plant-Based Diets As A Healthy Choice 2Health News:New Book Presents Health Professionals With A Fully-Referenced, Meticulous Overview of the Research on Plant-Based Diets As A Healthy Choice 3Health News:Mommylish Launches Its Website 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2
... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: